ATE413388T1 - Muskarin antagonisten - Google Patents

Muskarin antagonisten

Info

Publication number: ATE413388T1
Authority: AT; Austria
Prior art keywords: sup; formula; compound; muscarine antagonists; methods
Prior art date: 2002-04-26

Application number

AT03726436T

Other languages

English (en)

Inventor

Craig Boyle

William Greenlee

Samuel Chackalamannil

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-26

Filing date

2003-04-24

Publication date

2008-11-15

2003-04-24 Application filed by Schering Corp filed Critical Schering Corp

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE413388T1 publication Critical patent/ATE413388T1/de

Links

UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT03726436T 2002-04-26 2003-04-24 Muskarin antagonisten ATE413388T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37609302P	2002-04-26	2002-04-26

Publications (1)

Publication Number	Publication Date
ATE413388T1 true ATE413388T1 (de)	2008-11-15

Family

ID=29270760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03726436T ATE413388T1 (de)	2002-04-26	2003-04-24	Muskarin antagonisten

Country Status (11)

Country	Link
US (1)	US6890936B2 (de)
EP (1)	EP1499596B1 (de)
JP (2)	JP4527408B2 (de)
CN (1)	CN1649845A (de)
AT (1)	ATE413388T1 (de)
AU (1)	AU2003228674A1 (de)
CA (1)	CA2484217A1 (de)
DE (1)	DE60324544D1 (de)
ES (1)	ES2315494T3 (de)
MX (1)	MXPA04010552A (de)
WO (1)	WO2003091220A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101880277A (zh)	2003-04-24	2010-11-10	因塞特公司	作为金属蛋白酶抑制剂的氮杂螺烷衍生物
CN101044134A (zh)	2004-09-20	2007-09-26	塔加西普特公司	具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
AU2007299920A1 (en) *	2006-09-19	2008-03-27	Braincells, Inc.	PPAR Mediated Modulation of Neurogenesis
AU2007299726A1 (en) *	2006-09-22	2008-03-27	Braincells, Inc.	Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080108574A1 (en) *	2006-09-27	2008-05-08	Braincells, Inc.	Melanocortin receptor mediated modulation of neurogenesis
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (de)	2006-11-30	2012-04-18	Probiodrug AG	Neue inhibitoren von glutaminylcyclase
CA2679446C (en)	2007-03-01	2016-05-17	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
TW200902007A (en) *	2007-05-25	2009-01-16	Astrazeneca Ab	Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) *	2008-11-25	2010-05-27	Astrazeneca Ab	Spirocyclobutyl Piperidine Derivatives
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
EP2533645B1 (de)	2010-02-09	2016-07-27	The Johns Hopkins University	Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
DK2545047T3 (da)	2010-03-10	2014-07-28	Probiodrug Ag	Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (de)	2010-04-21	2016-01-06	Probiodrug AG	Hemmer der glutaminylzyklase
US20110281853A1 (en)	2010-05-12	2011-11-17	Rishi Arora	Compositions and methods for treating or preventing atrial fibrillation
WO2012123563A1 (en)	2011-03-16	2012-09-20	Probiodrug Ag	Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
EP2968220B1 (de)	2013-03-15	2021-05-05	Agenebio, Inc.	Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
EP2968237A4 (de)	2013-03-15	2016-08-31	Univ Johns Hopkins	Verfahren und zusammensetzungen zur verbesserung der kognitiven funktion
SG11201702982UA (en)	2014-10-31	2017-05-30	Indivior Uk Ltd	Dopamine d3 receptor antagonists compounds
MX384391B (es)	2015-05-22	2025-03-14	Agenebio Inc	Composiciones farmacéuticas de levetiracetam de liberación extendida.
AU2018300980A1 (en) *	2017-07-12	2020-01-02	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor M4
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
US11299481B2 (en)	2017-10-20	2022-04-12	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor M4
EP3732163A4 (de) *	2017-12-20	2021-07-14	Vanderbilt University	Antagonisten des muskarinischen acetylcholinrezeptors m4
TWI767148B (zh) *	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04225953A (ja) *	1990-05-07	1992-08-14	Shionogi & Co Ltd	スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) *	1993-05-07	1993-06-23	Res Inst Medicine Chem	Chemical compounds
WO1999032489A1 (en) *	1997-12-23	1999-07-01	Alcon Laboratories, Inc.	Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CA2444595A1 (en) *	2001-04-20	2002-10-31	Banyu Pharmaceutical Co., Ltd.	Benzimidazolone derivatives

2003
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 EP EP03726436A patent/EP1499596B1/de not_active Expired - Lifetime
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ES2315494T3 (es)	2009-04-01
MXPA04010552A (es)	2005-01-25
US6890936B2 (en)	2005-05-10
WO2003091220A1 (en)	2003-11-06
US20040067972A1 (en)	2004-04-08
JP4527408B2 (ja)	2010-08-18
HK1068136A1 (en)	2005-04-22
EP1499596B1 (de)	2008-11-05
EP1499596A1 (de)	2005-01-26
CA2484217A1 (en)	2003-11-06
AU2003228674A1 (en)	2003-11-10
DE60324544D1 (de)	2008-12-18
JP2006507220A (ja)	2006-03-02
JP2010059213A (ja)	2010-03-18
CN1649845A (zh)	2005-08-03

Legal Events

Date	Code	Title	Description
2009-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE413388T1 (de)	2008-11-15	Muskarin antagonisten
IL166271A0 (en)	2006-01-15	Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
UA88012C2 (uk)	2009-09-10	Похідні хіназоліндіону як інгібітори parp
SE0101675D0 (sv)	2001-05-11	Novel composition
ATE433447T1 (de)	2009-06-15	Pyrimiidinverbindungen
BRPI0410630A (pt)	2006-06-13	antagonista de nk1
ATE478664T1 (de)	2010-09-15	Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE453393T1 (de)	2010-01-15	Verwendung von pyridylamiden als angiogenesehemmer
IS6658A (is)	2002-12-17	Ný efnasambönd
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DE69725825D1 (de)	2003-12-04	5-HT1F-Agonisten
BR0307833A (pt)	2004-12-07	Sìntese controlada de ziprasidona e suas composições
ATE374190T1 (de)	2007-10-15	Tetrahydrochinazolinderivate als cfr-antagonisten
ATE377602T1 (de)	2007-11-15	Morphinanderivate und ihre medizinische anwendung
PL376324A1 (en)	2005-12-27	Piperazinyl and diazapanyl benzamides and benzthioamides
DE60323942D1 (de)	2008-11-20	Lipase-hemmende zusammensetzung
ATE498600T1 (de)	2011-03-15	Inden derivate als pharmazeutika
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BG105710A (en)	2002-02-28	5ht1 antagonists for antidepressant therapy
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
BR0212899A (pt)	2004-11-03	Compostos orgânicos
ATE335739T1 (de)	2006-09-15	Cak inhibitoren und deren verwendungen
NO20002408D0 (no)	2000-05-09	5-HT1F antagonister
DE60133914D1 (de)	2008-06-19	Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1,2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide
GB0223223D0 (en)	2002-11-13	Organic compounds